Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

How to Discontinue Antiplatelet Therapy Prior Non-Cardiac Surgery

Both the indication and discontinuation of antiplatelet therapy to balance ischemic-bleeding risks has been left to physician criterion.  However, leaving the decision to one single specialist might not be the best. This is when the team’s role becomes essential. 

Cómo suspender la antiagregación previa a una cirugía no cardíaca

This study looked at the advantages consensus decision-making amongst clinicians, surgeons and anesthesiologists to continue or not antiplatelet therapy in patients with second generation drug eluting stents (DES) prior a non-cardiac surgery. 

3582 patients with prior DES stenting receiving non-cardiac surgery were retrospectively included. 3103 patients consulted with the team and follow their recommendation. 

Patients on arbitrarily managed dual antiplatelet therapy (DAPT) before or during surgery presented higher risk of bleeding during surgery and more emergency surgery. These patients were more frequently women and were on DAPT at consultation. 

Arbitrary DAPT decision making nearly doubled the risk of net clinical adverse events  (OR 1.98, CI 95%, 1.98–3.11), tripled cardiovascular events (OR 3.11; CI 95%, 1.31–7.34) and doubled major bleeding (OR 2.34; CI 95%, 1.45–3.76).


Read also: Watch again our Webinar “SOLACI@BIOTRONIK” on our Youtube account.


This association was consistent irrespective of non-cardiac surgery, risk or recommendation on DAPT management. 

Conclusion

DAPT management prior non-cardiac surgery should be decided on a case-by-case basis, and all involved in the procedure should have a say (cardiologist, surgeon, anesthesiologist, etc.). 

The risk of major adverse events have a two and three-fold increase when DAPT management is arbitrary and individually made by a single team member. 

Original title: Consensus Decision-Making for the Management of Antiplatelet Therapy before Non-Cardiac Surgery in Patients Who Underwent Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents: A Cohort Study.

Reference: Choongki Kim et al. J Am Heart Assoc. 2021 Apr 20;10(8):e020079. doi: 10.1161/JAHA.120.020079.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...